Skip to content Skip to sidebar Skip to footer
Subscribe Now
Viewpoints_Dr. Andrew Krivoshik
VIEWPOINTS

PharmaShots Interview: Astellas’ Dr. Andrew Krivoshik Shares Insights on P-II FAST Study of Zolbetuximab

In an interview with PharmaShots, Dr. Andrew Krivoshik, Senior Vice President and Oncology Therapeutic Area Head at Astellas, shared his views on the P-II FAST study result published in the journal Gastric Cancer and highlights the data published in Annals of Oncology. Shots: The data from P-II FAST study evaluating zolbetuximab + EOX in 1L patients with advanced gastric and…
July 26, 20210Comments

Read more

Viewpoints_Tony Ezell
VIEWPOINTS

PharmaShots Interview: BD’s Tony Ezell Shares Insights on the Collaboration with USATF to Provide COVID – 19 Testing for US Athletes

In an interview with PharmaShots, Tony Ezell, President, North America and Chief Marketing Officer, BD shares its agreement with the USA Track and Field team for COVID-19 testing for the Olympic Trials. Shots: BD's partnership with USATF is part of the company's commitment to helping get people back to their normal lives The BD Veritor…
July 21, 20210Comments

Read more

Thoughtspot_Senior Editor
THOUGHTSPOT

Ethno-Pharma- An Emerging Sector

The Healthcare sector in 2021 is evolving to a greater extent owing to the initiatives and advancements taking place to futureproof the healthcare facilities from uncertain, unwanted, and deadly events like Covid-19. These advancements are happening while keeping the patients at the center with more focus on preventive and immune health.  Now while talking about…
July 21, 20210Comments

Read more

Viewpoints_Dave Marek
VIEWPOINTS

PharmaShots Interview: Myovant’s Dave Marek Shares Insights on the US FDA’s Approval of Myfembree in Uterine Fibroids

In an interview with PharmaShots, Dave Marek. CEO of Myovant shares insights on the US FDA's approval of Myfembree (relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5mg) in Uterine Fibroids. Shots: The US FDA has approved Myovant & Pfizer's Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as the first once-daily treatment for the…
July 20, 20210Comments

Read more

Viewpoints_Mark Wildgust, Paolo Ghia & Paul Barr
VIEWPOINTS

PharmaShots Interview: Janssen’s Mark Wildgust along with Two Other Key Speakers Share Insights on Data Presented at ASCO 2021

In an interview with PharmaShots, Mark Wildgust, VP of Global Medical Affairs, Oncology at Janssen, Dr. Paolo Ghia, Division of Experimental Oncology at Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele and Paul Barr, Associate Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Institute at University of Rochester…
July 19, 20210Comments

Read more

Viewpoints_Denis Corin
VIEWPOINTS

PharmaShots Interview: Q BioMed’s Denis Corin Shares Insights on the Agreement to Serve US Department of Defense and Veterans Affairs

In an interview with PharmaShots, Denis Corin, Chief Executive Officer and Chairman of the Board at Q BioMed share his views on the supply agreement for Strontium89 with the US Department of Defense and Veterans Affairs. Shots: BioMed has signed a 5-year agreement to commercially serve the US Department of Veterans Affairs (VA) and Department of Defense…
July 13, 20210Comments

Read more

Viewpoints_Dr. Ramon Mohanlal
VIEWPOINTS

PharmaShots Interview: BeyondSpring’s Dr. Ramon Mohanlal Shares Insights on the Data of Triple Combo Plinabulin Presented at ASCO 2021

In an interview with PharmaShots, Ramon Mohanlal, M.D., Ph.D., MBA, Chief Medical Officer and Executive Vice President of Research and Development at BeyondSpring share his views on the data of triple combination regimen presented at ASCO and also shed light on the impact of plinabulin on SCLC. Shots: Plinabulin in combination with nivolumab and ipilimumab showed 46% ORR with one…
July 12, 20210Comments

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]